New data from Cognito Therapeutics has indicated that its Spectris device increases cerebrospinal fluid (CSF) HDL-like lipid transport particles, suggesting the neuromodulation therapy prompts a ...
CAMBRIDGE, Mass., July 13, 2026--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage neurotechnology company developing novel therapies for neurodegenerative disorders, today announced the ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the publication of a study in ...
Unbiased cerebrospinal fluid proteomics identify coordinated increases in HDL-like lipid transport proteins and myelination pathways following investigational Spectris™ sensory stimulation Cognito ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results